Colistin past and future: A bibliographic analysis

Journal of Critical Care

Volumn 28, Issue 2, 2013, Pages 219.e13-219.e19

  Azzopardi, Ernest A ^a,b   Ferguson, Elaine L ^a   Thomas, David W ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

Author keywords

Colistin; Literature trends, redevelopment

Indexed keywords

COLISTIN;

ADVERSE OUTCOME; CONTROLLED STUDY; DATA ANALYSIS; DATA SYNTHESIS; HUMAN; INTERDISCIPLINARY RESEARCH; MEDICAL LITERATURE; MULTIDRUG RESISTANCE; PROCESS OPTIMIZATION; PUBLICATION; QUALITATIVE ANALYSIS; REVIEW; STANDARDIZATION; TREND STUDY;

EID: 84875384834     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2012.04.008     Document Type: Review

References (71)

1. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12.
2. Falagas M.E., Michalopoulos A. Polymyxins: old antibiotics are back. Lancet 2006, 367:633-634.
3. Garfield E., Merton R.K. Citation indexing: its theory and application in science, technology, and humanities 1979, Wiley, New York.
4. Aminov R.I. A brief history of the antibiotic era: lessons learned and challenges for the future. Frontiers. Microbiology 2010, 1.
5. Morel C., Mossialos E. Stoking the antibiotic pipeline. Br Med J 2010, 340:c2115.
6. Beal J.L., Foissac J.C., Fourre M., Blettery B. Neurological toxicity of colistine methane sulfonate, about a case (author's transl). Toxicol Eur Res 1979, 2:55-58.
7. Snavely S.R., Hodges G.R. The neurotoxicity of antibacterial agents. Ann Intern Med 1984, 101:92-104.
8. Fernandes P. Antibacterial discovery and development-the failure of success?. Nat Biotechnol 2006, 24:1497-1503.
9. Nation R.L., Li J. Optimizing use of colistin and polymyxin B in the critically ill 2007, 604-614. Thieme Medical Publishers, c1994-, New York.
10. Healy D.P., Sombun A.D., Gardner J.C., Good K., Durkee P.J., Toner L., et al. Pharmacokinetics of colistin in an adolescent boy with extensive burn injury. J Burn Care Res 2011, 32:e7.
11. Li J., Nation R.L., Turnidge J.D., Milne R.W., Coulthard K., Rayner C.R., et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601.
12. Karageorgopoulos D.E., Falagas M.E. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008, 8:751-762.
13. Sinirtas M., Akalin H., Gedikoglu S. Investigation of colistin sensitivity via three different methods in Acinetobacter baumannii isolates with multiple antibiotic resistance. Int J Infect Dis 2009, 13:e217-e220.
14. Dizbay M., Altuncekic A., Sezer B.E., Ozdemir K., Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008, 32:29-32.
15. Gales A.C., Jones R.N., Sader H.S. Contemporary activity of colistin and polymyxin B against a worldwide collection of gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011, 66:2070-2074.
16. Hernan R.C., Karina B., Gabriela G., Marcela N., Carlos V., Angela F. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009, 65:188-191.
17. Tan T.Y., Ng S.Y. The in-vitro activity of colistin in Gram-negative bacteria. Singapore Med J 2006, 47:621-624.
18. Ko K.S., Suh J.Y., Kwon K.T., Jung S.-I., Park K.-H., Kang C.I., et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007, 60:1163-1167.
19. Antoniadou A., Kontopidou F., Poulakou G., Koratzanis E., Galani I., Papadomichelakis E., et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007, 59:786-790.
20. Gilad J., Eskira S., Riesenberg K., Schlaeffer F., Hyam E., Borer A. Emergence of nosocomial colistin-resistant Acinetobacter baumannii. Program and abstracts of the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC) 2005, 333. American Society for Microbiology, Washington, DC.
21. Conrad R.S., Galanos C. Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance. Antimicrob Agents Chemother 1989, 33:1724.
22. Groisman E.A., Kayser J., Soncini F.C. Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J Bacteriol 1997, 179:7040.
23. Vaara M., Vaara T. Polycations as outer membrane-disorganizing agents. Antimicrob Agents Chemother 1983, 24:114.
24. Nicas T.I., Hancock R. Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol 1980, 143:872.
25. Brown M., Collier P., Gilbert P. Influence of growth rate on susceptibility to antimicrobial agents: modification of the cell envelope and batch and continuous culture studies. Antimicrob Agents Chemother 1990, 34:1623.
26. Adams M.D., Nickel G.C., Bajaksouzian S., Lavender H., Murthy A.R., Jacobs M.R., et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009, 53:3628-3634.
27. Fu W., Yang F., Kang X., Zhang X., Li Y., Xia B., et al. First structure of the polymyxin resistance proteins. Biochem Biophys Res Commun 2007, 361:1033-1037.
28. Sabuda D.M., Laupland K., Pitout J., Dalton B., Rabin H., Louie T., et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol. 2008, 19:413-418.
29. Velkov T., Thompson P.E., Nation R.L., Li J. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2009, 53:1898-1916.
30. Oh J.T., Cajal Y., Skowronska E.M., Belkin S., Chen J., Van Dyk T.K., et al. Cationic peptide antimicrobials induce selective transcription of micF and osmY in Escherichia coli. Biochim Biophys Acta 2000, 1463:43-54.
31. Li X.Z., Zhang L., Poole K. Interplay between the MexA-MexB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 2000, 45:433.
32. Germ M., Yoshihara E., Yoneyama H., Nakae T. Interplay between the efflux pump and the outer membrane permeability barrier in fluorescent dye accumulation in Pseudomonas aeruginosa. Biochem Biophys Res Commun 1999, 261:452-455.
33. Lin B., Zhang C., Xiao X. Toxicity, bioavailability and pharmacokinetics of a newly formulated colistin sulfate solution. J Vet Pharmacol Ther 2005, 28:349-354.
34. Orwa J.A., Govaerts C., Busson R., Roets E., Van Schepdael A., Hoogmartens J. Isolation and structural characterization of colistin components. J Antibiot (Tokyo) 2001, 54:595-599.
35. Kline T., Holub D., Therrien J., Leung T., Ryckman D. Synthesis and characterization of the colistin peptide polymyxin E1 and related antimicrobial peptides. J Pept Res 2001, 57:175-187.
36. Thomas A., Thomas J., Holloway I. Microbiological and chemical analysis of polymyxin B and polymyxin E (colistin) sulphates. Analyst 1980, 105:1068-1075.
37. Govaerts C., Rozenski J., Orwa J., Roets E., Van Schepdael A., Hoogmartens J. Mass spectrometric fragmentation of cyclic peptides belonging to the polymyxin and colistin antibiotics studied by ion trap and quadrupole/orthogonal-acceleration time-of-flight technology. Rapid Commun Mass Spectrom 2002, 16:823-833.
38. Govaerts C., Orwa J., Van Schepdael A., Roets E., Hoogmartens J. Liquid chromatography-ion trap tandem mass spectrometry for the characterization of polypeptide antibiotics of the colistin series in commercial samples. J Chromatogr A 2002, 976:65-78.
39. Ma Z., Wang J., Gerber J.P., Milne R.W. Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 862:205-212.
40. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003, 47:1766.
41. Decolin D., Leroy P., Nicolas A., Archimbault P. Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues. J Chromatogr Sci 1997, 35:557-564.
42. Mares J., Kumaran S., Gobbo M., Zerbe O. Interactions of lipopolysaccharide and polymyxin studied by NMR spectroscopy. J Biol Chem 2009, 284:11498-11506.
43. Pristovsek P., Kidric J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study‡. J Med Chem 1999, 42:4604-4613.
44. Ikai Y., Oka H., Hayakawa J., Kawamura N., Mayumi T., Suzuki M., et al. Total structures of colistin minor components. J Antibiot 1998, 51:492-498.
45. Orwa J.A., Govaerts C., Gevers K., Roets E., Van Schepdael A., Hoogmartens J. Study of the stability of polymyxins B(1), E(1) and E(2) in aqueous solution using liquid chromatography and mass spectrometry. J Pharm Biomed Anal 2002, 29:203-212.
46. Plachouras D., Karvanen M., Friberg L., Papadomichelakis E., Antoniadou A., Tsangaris I., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 2009, 53:3430-3436.
47. Hartzell J.D., Neff R., Ake J., Howard R., Olson S., Paolino K., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728.
48. Ganapathy H., Pal S.K., Teare L., Dziewulski P. Use of colistin in treating multi-resistant Gram-negative organisms in a specialised burns unit. Burns 2009, 36:522-527.
49. Cheng C.Y., Sheng W.H., Wang J.T., Chen Y.C., Chang S.C. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents 2009, 35:297-300.
50. Pintado V., San Miguel L.G., Grill F., Mejia B., Cobo J., Fortun J., et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect 2008, 56:185-190.
51. Falagas M.E., Kasiakou S.K. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006, 10:R27.
52. Evagelopoulou P., Katsaros A., Myrianthefs P., Karatzas S., Boutzouka E., Fildissis G., et al. Colistin and rhabdomyolysis: a causative agent or an innocent bystander?. Intensive Care Med 2007, 33:556-557.
53. Yau W., Owen R.J., Poudyal A., Bell J.M., Turnidge J.D., Yu H.H., et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 2009, 58:138-144.
54. Lim L.M., Ly N., Anderson D., Yang J.C., Macander L., Jarkowski A., et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy 2010, 30:1279-1291.
55. Huang J., Tang Y.Q., Sun J.Y. Intravenous colistin sulfate: a rarely used form of polymyxin E for the treatment of severe multidrug-resistant Gram-negative bacterial infections. Scand J Infect Dis 2010, 42:267-269.
56. Conly J., Johnston B. Colistin: the phoenix arises. Can J Infect Dis Med Microbiol 2006, 17:267-269.
57. Tan T.Y., Ng L.S.Y., Tan E., Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007, 60:421.
58. Owen R.J., Li J., Nation R.L., Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007, 59:473-477.
59. Poudyal A., Howden B.P., Bell J.M., Gao W., Owen R.J., Turnidge J.D., et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008, 62:1311.
60. Vaara M., Fox J., Loidl G., Siikanen O., Apajalahti J., Hansen F., et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob Agents Chemother 2008, 52:3229-3236.
61. Molina J., Cordero E., Pachón J. New information about the polymyxin/colistin class of antibiotics. Expert Opin Pharmacother 2009, 10:2811-2828.
62. Chirihara S., Tobita T., Yahata M., Ito A., Koyama Y. Enzymatic degradation of colistin isolation and identification of α-N-acyl α, γ-diaminobutyric acid and colistin nonapeptide. Agric Biol Chem 1973, 37:2455-2463.
63. Okimura K., Ohki K., Sato Y., Ohnishi K., Sakura N. Semi-synthesis of polymyxin B (2-10) and colistin (2-10) analogs employing the trichloroethoxycarbonyl (Troc) group for side chain protection of alpha, gamma-diaminobutyric acid residues. Chem Pharm Bull (Tokyo) 2007, 55:1724-1730.
64. Nakajima K. Structure-activity relationship of colistins. Chem Pharm Bull 1967, 15:1219.
65. Bucklin S.E., Lake P., Logdberg L., Morrison D.C. Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob Agents Chemother 1995, 39:1462-1466.
66. Thomas D, Walsh T, Ferguson E. Therapeutic Conjugates. GB 1010500.5. In: UKIPO, editor. UK 2010.
67. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 1992, 56:395-411.
68. Clausell A., Garcia-Subirats M., Pujol M., Busquets M., Rabanal F., Cajal Y. Gram-negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J Phys Chem B 2007, 111:551-563.
69. Barnett M., Bushby S., Wilkinson S. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1964, 23:552.
70. Beveridge E., Martin A. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol Chemother 1967, 29:125.
71. Azzopardi E., Ferguson E., Thomas D. Polymer therapeutics for effective antimicrobial targeting in burn injury. Br J Surg 2011, 98(S2). (Abstract).